Cancer Research UK, Abcam partner on cancer antibodies

By The Science Advisory Board staff writers

July 8, 2020 -- Abcam will create protein-based reagents for targets identified by Cancer UK-funded researchers. Antibodies that result from the partnership will be used to further understand cancer biology, create new diagnostic tools, and potentially develop novel therapies.

Under the terms of the agreement, the Cancer UK-funded researchers can request Abcam to supply antibodies developed from the partnership for an agreed period of exclusivity. After the unspecified period of exclusivity ends, Abcam will utilize its supply capability to make the antibodies available to the wider research and diagnostic development community.

If you like this content, please share it with a colleague!

Related Reading

Communication of cancer cells analyzed with organoids and novel cytometry
A new technique using organoids, self-organizing 3D tissue models, can decipher how individual cancer cells communicate with each other and the unique...

New targeted therapy for lung cancer using precious metals as Trojan exosomes
Researchers at the University of Edinburgh and the Universidad de Zaragoza in Spain present a novel therapeutic approach to treating cancer on September...

The “Two-Headed Monster”: Vendors Tackle Antibody Validation
The Science Advisory Board examined the preferences of scientists regarding the purchase and use of antibodies, as well as customer trust, satisfaction,...

Finding the Right Match - How Scientists See Antibody Suppliers
We at The Science Advisory Board recognize that scientific customers can exhibit remarkable brand loyalty. When we explored the antibody market in 2012,...

Research Antibodies - Friend or Foe?
Research antibodies are used in basic and clinical research because they recognize and bind to specific antigens, receptors, infectious organisms, and...